New biologic shows promise for Tough-to-Treat ulcerative colitis
Disease control
Completed
This study tested whether mirikizumab, a biologic drug, can improve symptoms and gut healing in 100 people with moderate-to-severe ulcerative colitis who had a specific type of inflammation seen on biopsy. Participants received either mirikizumab or vedolizumab, and doctors track…
Phase: PHASE4 • Sponsor: Showa Inan General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC